Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Inclusion Criteria: * Male or female patients with a histologically or cytologically diagnosed malignant solid tumour * Adequate bone marrow, hepatic and renal function * Performance status of no more than 2 ( ECOG scale). Exclusion Criteria: * Any chemotherapy, radiotherapy ( except palliative), endocrine or immunotherapy within 4 weeks prior to entry * Major surgery with 4 weeks of entering the study and must have recovered from effects of the major surgery * More than two previous courses of platinum-containing chemotherapy * Heavily pre-treated patients(\> 2 courses of previous chemotherapy and/or extensive irradiation leading to bone marrow deficiency) will be excluded from the study